Barclays
CRBU icon

Barclays’s Caribou Biosciences CRBU Stock Holding History

Barclays’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.8K Buy
26,713
+5,025
+23% +$8.63K ﹤0.01% 4319
2025
Q4 		$34.5K Sell
21,688
-84
-0.4% -$176 ﹤0.01% 4796
2025
Q3 		$50.7K Buy
21,772
+84
+0.4% +$159 ﹤0.01% 4763
2025
Q2 		$27.3K Sell
21,688
-82,720
-79% -$81.4K ﹤0.01% 4802
2025
Q1 		$95.3K Sell
104,408
-41,009
-28% -$53.3K ﹤0.01% 4428
2024
Q4 		$231K Buy
145,417
+15,578
+12% +$31.3K ﹤0.01% 4237
2024
Q3 		$254K Buy
129,839
+71,463
+122% +$146K ﹤0.01% 4177
2024
Q2 		$95.7K Sell
58,376
-38,857
-40% -$124K ﹤0.01% 3929
2024
Q1 		$500K Sell
97,233
-166,238
-63% -$1.03M ﹤0.01% 3594
2023
Q4 		$1.51M Buy
263,471
+9,240
+4% +$45.7K ﹤0.01% 3137
2023
Q3 		$1.22M Buy
254,231
+236,020
+1,296% +$1.46M ﹤0.01% 2188
2023
Q2 		$77.4K Sell
18,211
-82,981
-82% -$373K ﹤0.01% 3660
2023
Q1 		$537K Sell
101,192
-18,899
-16% -$118K ﹤0.01% 3222
2022
Q4 		$754K Buy
120,091
+36,690
+44% +$326K ﹤0.01% 3030
2022
Q3 		$880K Buy
83,401
+80,692
+2,979% +$752K ﹤0.01% 2331
2022
Q2 		$15K Sell
2,709
-5,660
-68% -$43.3K ﹤0.01% 4499
2022
Q1 		$77K Buy
+8,369
New +$88.2K ﹤0.01% 3910

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's CRBU Position: Q1 2026 in Review

Barclays increased its Caribou Biosciences (CRBU) stake by 23% in Q1 2026, buying an estimated $8.63K and bringing the position to 26,713 shares worth $50.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4319.

Barclays first reported a position in CRBU in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.51M in Q4 2023. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Barclays held 26,713 shares of Caribou Biosciences worth $50.8K as of Q1 2026.
  • Barclays bought 5,025 Caribou Biosciences shares in Q1 2026, an estimated $8.63K.
  • Caribou Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4319 holding.
  • Barclays first reported a position in Caribou Biosciences in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Caribou Biosciences position peaked at $1.51M in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.